Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.

AIDS research and human retroviruses - 1 Sept 2007

Poveda Eva, Briz Veronica, Paraskevis Dimitrios, Barreiro Pablo, Hatzakis Angelos, Soriano Vincent

Abstract excerpt

Genetic analysis of HIV-1 gp41 in plasma and peripheral blood mononuclear cell (PBMC) compartments was performed longitudinally in 10 HIV-infected patients treated with enfuvirtide. The appearance of enfuvirtide resistance mutations in PBMCs (DNA) generally occurred after (from 23 to 157 weeks) being recognizable in plasma (RNA). The disappearance of drug-resistant HIV-1 mutations to enfuvirtide in seven patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Resistance, Viral
Share to Enfuvirtide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HIV Envelope Protein gp41

Share to HIV Fusion Inhibitors

Share to Leukocytes, Mononuclear

Share to Peptide Fragments

Share to Salvage Therapy

Share to Treatment Failure

Source

Identifiers

PMID: 17919101
DOI: 10.1089/aid.2006.0287

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.PMID 17919101Read ↗

Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.Semantic proximity Read ↗

Variants with different mutation patterns persist in the quasispecies of enfuvirtide-resistant HIV-1 population during and after treatment in vivo.Semantic proximity Read ↗

Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.Semantic proximity Read ↗

A cohort study of enfuvirtide immunological and virological efficacy in clinical practice.Semantic proximity Read ↗

Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen.Semantic proximity Read ↗

Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment.Semantic proximity Read ↗

Unexpected dramatic increase in CD4+ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations.Semantic proximity Read ↗

Rapid emergence of enfuvirtide resistance in HIV-1-infected patients: results of a clonal analysis.Semantic proximity Read ↗

Viral dynamics and in vivo fitness of HIV-1 in the presence and absence of enfuvirtide.Semantic proximity Read ↗

Association between specific enfuvirtide resistance mutations and CD4 cell response during enfuvirtide-based therapy.Semantic proximity Read ↗

In vivo selection by enfuvirtide of HIV type-1 env quasispecies with optimal potential for phenotypic expression of HR1 mutations.Semantic proximity Read ↗

Primary resistance to enfuvirtide (T20) in recently HIV-1 infected, antiretroviral-naive patients from the ANRS Aquitaine Cohort.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.